Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GXLDF$0.200.00(0.00%)Hi-View Resources Inc. to Attend the 52nd Annual New Orleans Investment Conference[9:30:00 AM ET]UBAB$62.000.00(0.00%)United Bancorporation of Alabama, Inc. Announces Third Quarter Results (OTCQX: UBAB) - United Bancorporation of Alabama, Inc. reported net income of $16.0 million for the nine months ended September 30, 2026, compared to ...[9:30:00 AM ET]KVHI$7.12-0.66(-8.48%)KVH Industries to Host Third Quarter Conference Call on November 5, 2026[9:22:13 AM ET]ARAI$0.11-0.01(-5.85%)Arrive AI to Report Q3 2026 Results and Host Webcast on November 13[9:19:00 AM ET]VIVK$1.34-0.16(-10.70%)Vivakor Announces Proposed Hydrogen Plant and Fueling Station at a Texas International Airport[9:15:00 AM ET]KBLB$0.080.00(0.00%)Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace[9:15:00 AM ET]CWBK$41.000.00(0.00%)CW Bancorp Reports Third Quarter 2026 Financial Results CW Bancorp (OTCQX: CWBK), the parent company ("the Company") of CommerceWest Bank (the "Bank") reported consolidated net income for the third quarter ...[9:15:00 AM ET]NTHI$3.16+0.04(+1.28%)NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage[9:10:00 AM ET]CURLF$8.52-0.07(-0.84%)Curaleaf Celebrates Graduation of Inaugural New York Incubator Program Class, Announces Future Cohorts and Multi-State Expansion Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer cannabis products, today announced the...[9:10:00 AM ET]PTHS$17.51+0.97(+5.86%)Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin[9:09:49 AM ET]IDAI$2.95+0.09(+3.15%)Trust Stamp Appointed Exclusive Technology Partner for AFCAS, Ghana’s National Fire Safety Digitisation Programme[9:07:00 AM ET]XE$11.07-0.63(-5.43%)NRC Completes Landmark Safety Review of X-energy’s Xe-100 SMR[9:06:55 AM ET]AKTX$8.00-1.20(-13.04%)Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit[9:05:00 AM ET]

VBIO · NASDAQ

Valion Bio, Inc.

$0.58 -0.04 (-6.96%)

Company overview

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.1M
Employees
52
Headquarters
San Antonio, TX
Website
valionbio.com
CEO
Michael R. Cavanaugh
Listed
November 11, 2021
P/E
-11.35
Dividend yield
0.00%

Company financials

Revenue
$1.7M
Gross profit
-$191,728
Operating income
-$3.5M
EBITDA
-$166,629
Net income
-$3.6M
EPS
-$0.05
Total assets
$120M
Total debt
$500,000
Gross margin
-11.32%
Net margin
-211.53%
Earnings yield
-8.81%

Revenue segmentation

By product (FY 2024)
By region (FY 2024)

No geographic segmentation.

Showing FY 2024

Price chart

-0.667.9516.5625.1733.78
VBIO 1D NASDAQ O0.64H0.70L0.62C0.62-0.06 (-8.16%)Vol39.54K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
VBIOValion Bio, Inc. Press release Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results ACCESS Newswire
VBIOValion Bio, Inc. Press release Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation ACCESS Newswire
VBIOValion Bio, Inc. Press release Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options ACCESS Newswire
VBIOValion Bio, Inc. Press release Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value ACCESS Newswire
VBIOValion Bio, Inc. Press release Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone ACCESS Newswire
VBIOValion Bio, Inc. Press release With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge ACCESS Newswire
VBIOValion Bio, Inc. Press release Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers ACCESS Newswire
VBIOValion Bio, Inc. Stock news New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod Accesswire
VBIOValion Bio, Inc. Press release 3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours GlobeNewswire
VBIOValion Bio, Inc. Stock news Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity Accesswire
VBIOValion Bio, Inc. Press release Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions ACCESS Newswire
VBIOValion Bio, Inc. Press release Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule ACCESS Newswire
VBIOValion Bio, Inc. Press release Valion Bio Announces Changes to Management and Board of Directors ACCESS Newswire
VBIOValion Bio, Inc. Press release Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase Accesswire
VBIOValion Bio, Inc. Press release Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury Accesswire
VBIOValion Bio, Inc. Press release Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway PRNewsWire
VBIOValion Bio, Inc. Press release World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market PRNewsWire
VBIOValion Bio, Inc. Press release Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion PRNewsWire
VBIOValion Bio, Inc. Press release AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS PRNewsWire
VBIOValion Bio, Inc. Stock news Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures GuruFocus
See more
FAQ

Questions about Valion Bio, Inc.

What does Valion Bio, Inc. do?
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
What is VBIO's market cap?
Valion Bio, Inc. (VBIO) is a listed stock with a live quote. The latest market cap on this page is $1.1M.
Where is Valion Bio, Inc. headquartered?
Valion Bio, Inc. is headquartered in San Antonio, TX.
How do I get VBIO news from the API?
Call GET /v1/news?tickers=VBIO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does VBIO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VBIO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the VBIO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs